Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378599 | 1.00 | CTSK (0.51) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL18055004 | 0.82 | CA1 (0.67) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL3375583 | 0.82 | CA1 (0.67) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL31127632 | 0.81 | CTSK (0.54) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL73696 | 0.80 | CTSK (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL73697 | 0.80 | CTSK (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL75827 | 0.80 | CTSK (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL24427425 | 0.79 | CA1 (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL56783 | 0.79 | CA1 (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL56671 | 0.79 | CA1 (0.53) | CTSKCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2678342-B1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| WO-2012000608-A2 | NOVEL BETA-AMINOALDEHYDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR CHEMICAL USE AS REACTIVE INTERMEDIATES | GLUESENKAMP KARL-HEINZ (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | CTSK 4805/4885CA1 4656/4885CA2 3967/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | CTSK 4805/4885CA1 4656/4885CA2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.